Generated by AI
Medpace Holdings, Inc. is a global clinical research organization that provides outsourced clinical development services for biotechnology, pharmaceutical, and medical device companies. Medpace supports the full clinical trial lifecycle, from Phase I through Phase IV, with services that include study design, project management, clinical monitoring, regulatory affairs, data management, biostatistics, medical writing, pharmacovigilance, and post-marketing support. The company also offers specialized laboratory and trial support capabilities such as central laboratory services, bioanalytical testing, imaging core laboratory services, and cardiac safety assessments. Medpace serves clients across North America, Europe, Asia, South America, Africa, and Australia, playing a central role in helping sponsors run complex clinical programs and advance medical products through development.
Website5375 Medpace Way
Cincinnati, OH, 45227
United States
The latest articles about MEDP.
Medpace Holdings reported third quarter 2026 adjusted EPS of $4.84 and revenue of $716 million, both above Zacks consensus estimates. The combination of an earnings beat and an estimated 14.3% long-term earnings growth rate highlights how Medpace Holdings is executing against demand for outsourced clinical development. We will examine how the Medpace Holdings investment narrative intersects with this earnings and revenue beat to reshape the risk-reward profile. See how Medpace Holdings’...
Summary of Oct 22's posts. Generated by AI.
Summary of Jul 23's posts. Generated by AI.
Summary of Jan 14's posts. Generated by AI.
Summary of Oct 22's posts. Generated by AI.
Investors talking about MEDP also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.